T-cell receptors targeting distinct FLT3-D835Y neoantigens display differential reactivity toward acute myeloid leukemia_flow_cytometry_data_7

Figure 6E / Figure S14B: FACS staining of lysis assay of FLT3-A2 and NPM1-A2 TCR-T cells with patient-derived AML sample 17124. Fluorochromes: Alexa Fluor 700 = CD123, APC = CD34, APC/Fire 810 = HLA-DR, APC-Fire 750 = CD54, BB700 = CD102, BUV395 = CD58, BUV496 = CD16, BUV563 = GPR56, BUV661 = CD163, BUV737 = LILRB4, BUV805 = CLL-1, BV421 = CD3 / CD4 / CD8, BV480 = HLA-A*02, BV605 = CD11c, BV650 = CD61, BV711 = CD206, BV750 = CD45RA, BV786 = HLA-DP, FITC = HLA-DQ, PE = CD33, PE-Cy5 = CD117, PE-Fire810 = CD38, PerCP = HLA class I, PE-Vio 615 = CD68, Spark Violet 538 = CD45, V450 = CD14, Zombie Red = viability dye. Figure S7: FACS staining of CMV-A2 TCR-T cells. Fluorochromes: Zombie Red = viability dye, Pacific Blue = CD8, APC = mouseTCRcbeta, PE = tetramer. Figure S11A,C: FACS staining of MOLM13-RES-AC cells (pre-treated with Crenolanib). Fluorochromes: Zombie Red = viability, BV650 = FLT3. Figure 14A: FACS staining of TCR-T cells transduced with the NPM1-A2 or the CMV-A2 TCR. Fluorochromes: Zombie Red = viability, Pacific Blue = CD8, APC = mouseTCRcbeta, PE = tetramer. Figure 14D: FACS staining of activity assay of NPM1-A2 TCR-T cells upon overnight coincubation with K562 cells transduced with HLA-A*02:01 pulsed with titrated concentrations of NPM1 mutant peptide CLAVEEVSL. Fluorochromes: Zombie Red = viability dye, Pacific Blue = CD8, BV711 = mouseTCRcbeta, APC = CD137.